New York State Common Retirement Fund Increases Stock Position in Replimune Group, Inc. (NASDAQ:REPL)

New York State Common Retirement Fund lifted its position in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 260.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 43,204 shares of the company's stock after purchasing an additional 31,231 shares during the period. New York State Common Retirement Fund owned about 0.06% of Replimune Group worth $523,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. grew its position in shares of Replimune Group by 24.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,317 shares of the company's stock worth $198,000 after purchasing an additional 3,177 shares in the last quarter. SG Americas Securities LLC grew its holdings in Replimune Group by 14.7% during the 4th quarter. SG Americas Securities LLC now owns 26,291 shares of the company's stock valued at $318,000 after buying an additional 3,374 shares in the last quarter. Creative Planning grew its stake in Replimune Group by 28.7% during the third quarter. Creative Planning now owns 21,047 shares of the company's stock valued at $231,000 after acquiring an additional 4,699 shares in the last quarter. MetLife Investment Management LLC grew its stake in Replimune Group by 21.5% during the third quarter. MetLife Investment Management LLC now owns 35,134 shares of the company's stock valued at $385,000 after acquiring an additional 6,216 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its stake in Replimune Group by 81.7% during the third quarter. BNP Paribas Financial Markets now owns 15,011 shares of the company's stock valued at $165,000 after acquiring an additional 6,748 shares in the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on REPL. BMO Capital Markets raised their price objective on Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. HC Wainwright lifted their price objective on shares of Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. JPMorgan Chase & Co. upped their target price on shares of Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Finally, Jefferies Financial Group increased their price target on shares of Replimune Group from $16.00 to $19.00 and gave the company a "buy" rating in a report on Wednesday, December 4th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $19.43.

Replimune Group Trading Down 2.0 %

Shares of REPL stock traded down $0.23 during trading hours on Friday, reaching $11.51. 486,420 shares of the stock were exchanged, compared to its average volume of 868,773. Replimune Group, Inc. has a 12-month low of $4.92 and a 12-month high of $17.00. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14. The company's 50-day moving average price is $12.74 and its 200-day moving average price is $12.05. The firm has a market capitalization of $886.44 million, a price-to-earnings ratio of -3.75 and a beta of 1.30.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.09). As a group, equities analysts anticipate that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Insider Activity at Replimune Group

In other news, CEO Sushil Patel sold 10,000 shares of the business's stock in a transaction on Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the completion of the sale, the chief executive officer now directly owns 202,014 shares of the company's stock, valued at approximately $2,509,013.88. The trade was a 4.72 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 8.80% of the stock is owned by company insiders.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.